These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15138759)

  • 1. Changes in food reward following smoking cessation: a pharmacogenetic investigation.
    Lerman C; Berrettini W; Pinto A; Patterson F; Crystal-Mansour S; Wileyto EP; Restine SL; Leonard DG; Shields PG; Epstein LH
    Psychopharmacology (Berl); 2004 Aug; 174(4):571-7. PubMed ID: 15138759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.
    David SP; Brown RA; Papandonatos GD; Kahler CW; Lloyd-Richardson EE; Munafò MR; Shields PG; Lerman C; Strong D; McCaffery J; Niaura R
    Nicotine Tob Res; 2007 Aug; 9(8):821-33. PubMed ID: 17654295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.
    Leventhal AM; David SP; Brightman M; Strong D; McGeary JE; Brown RA; Lloyd-Richardson EE; Munafò M; Uhl GR; Niaura R
    Pharmacogenomics J; 2012 Feb; 12(1):86-92. PubMed ID: 20661272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.
    Cox LS; Nollen NL; Mayo MS; Choi WS; Faseru B; Benowitz NL; Tyndale RF; Okuyemi KS; Ahluwalia JS
    J Natl Cancer Inst; 2012 Feb; 104(4):290-8. PubMed ID: 22282543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.
    Lerman C; Shields PG; Wileyto EP; Audrain J; Hawk LH; Pinto A; Kucharski S; Krishnan S; Niaura R; Epstein LH
    Health Psychol; 2003 Sep; 22(5):541-8. PubMed ID: 14570538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.
    David SP; Strong DR; Munafò MR; Brown RA; Lloyd-Richardson EE; Wileyto PE; Evins AE; Shields PG; Lerman C; Niaura R
    Nicotine Tob Res; 2007 Dec; 9(12):1251-7. PubMed ID: 18058343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
    Aubin HJ; Lebargy F; Berlin I; Bidaut-Mazel C; Chemali-Hudry J; Lagrue G
    Addiction; 2004 Sep; 99(9):1206-18. PubMed ID: 15317642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence for a major role of polymorphisms during bupropion treatment.
    Hu J; Redden DT; Berrettini WH; Shields PG; Restine SL; Pinto A; Lerman C; Allison DB
    Obesity (Silver Spring); 2006 Nov; 14(11):1863-7. PubMed ID: 17135598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.
    David SP; Strong DR; Leventhal AM; Lancaster MA; McGeary JE; Munafò MR; Bergen AW; Swan GE; Benowitz NL; Tyndale RF; Conti DV; Brown RA; Lerman C; Niaura R
    Addiction; 2013 Dec; 108(12):2202-11. PubMed ID: 23941313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bupropion and cognitive behavioral therapy for weight-concerned women smokers.
    Levine MD; Perkins KA; Kalarchian MA; Cheng Y; Houck PR; Slane JD; Marcus MD
    Arch Intern Med; 2010 Mar; 170(6):543-50. PubMed ID: 20308641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?
    David SP; Niaura R; Papandonatos GD; Shadel WG; Burkholder GJ; Britt DM; Day A; Stumpff J; Hutchison K; Murphy M; Johnstone E; Griffiths SE; Walton RT
    Nicotine Tob Res; 2003 Dec; 5(6):935-42. PubMed ID: 14668077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.
    Ahluwalia JS; Harris KJ; Catley D; Okuyemi KS; Mayo MS
    JAMA; 2002 Jul 24-31; 288(4):468-74. PubMed ID: 12132977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.
    Swan GE; Valdes AM; Ring HZ; Khroyan TV; Jack LM; Ton CC; Curry SJ; McAfee T
    Pharmacogenomics J; 2005; 5(1):21-9. PubMed ID: 15492764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications.
    Perkins KA; Lerman C; Karelitz JL; Jao NC; Chengappa KN; Sparks GM
    Addiction; 2013 Nov; 108(11):1962-8. PubMed ID: 23773319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.
    Tonstad S; Farsang C; Klaene G; Lewis K; Manolis A; Perruchoud AP; Silagy C; van Spiegel PI; Astbury C; Hider A; Sweet R
    Eur Heart J; 2003 May; 24(10):946-55. PubMed ID: 12714026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees.
    Dalsgareth OJ; Hansen NC; Søes-Petersen U; Evald T; Høegholm A; Barber J; Vestbo J
    Nicotine Tob Res; 2004 Feb; 6(1):55-61. PubMed ID: 14982688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
    Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
    Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediating mechanisms for the impact of bupropion in smoking cessation treatment.
    Lerman C; Roth D; Kaufmann V; Audrain J; Hawk L; Liu A; Niaura R; Epstein L
    Drug Alcohol Depend; 2002 Jul; 67(2):219-23. PubMed ID: 12095672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.
    Tønnesen P; Tonstad S; Hjalmarson A; Lebargy F; Van Spiegel PI; Hider A; Sweet R; Townsend J
    J Intern Med; 2003 Aug; 254(2):184-92. PubMed ID: 12859700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.